A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Janssen Research & Development, LLC
Start Date
July 27, 2021
End Date
June 30, 2026
Administered By
Duke Cancer Institute
Awarded By
Janssen Research & Development, LLC
Start Date
July 27, 2021
End Date
June 30, 2026